Fuzzy
Algorithms
Benzofurans
/ therapeutic use
Biomarkers
/ metabolism
Cerebral Infarction
/ drug therapy
Drug Therapy, Combination
Edaravone
/ therapeutic use
Endothelium, Vascular
/ cytology
Female
Follow-Up Studies
Fuzzy Logic
Humans
Image Interpretation, Computer-Assisted
/ methods
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Neuroprotective Agents
/ therapeutic use
Prognosis
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
05
2021
accepted:
05
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
This paper aimed to discuss the denoising ability of magnetic resonance imaging (MRI) images based on fuzzy C-means clustering (FCM) algorithm and the influence of Butylphthalide combined with Edaravone treatment on nerve function and vascular endothelial function in patients with acute cerebral infarction (ACI). Based on FCM algorithm, Markov Random Field (MRF) model algorithm was introduced to obtain a novel algorithm (NFCM), which was compared with FCM and MRF algorithm in terms of misclassification rate (MCR) and difference of Kappa index (KI). 90 patients with ACI diagnosed in hospital from December 2018 to December 2019 were selected as subjects, who were divided into combined treatment group (conventional treatment + Edaravone + Butylphthalide) and Edaravone group (conventional treatment + Edaravone) randomly, each consisting of 45 cases. The National Institutes of Health Stroke Scale (NIHSS) score and endothelial function index level such as plasma nitric oxide (NO), human endothelin-1 (ET-1), and vascular endothelial cell growth factor (VEGF) were compared before and after treatment between the two groups. The results showed that the MCR of NFCM was evidently inferior to FCM and MRF, and the KI was notably higher relative to the other two algorithms. After treatment, the NIHSS score of the combined treatment group was (9.09 ± 1.86) points and that of Edaravone group was (14.97 ± 3.44) points, with evident difference between the two groups (
Identifiants
pubmed: 34354551
doi: 10.1155/2021/4080305
pmc: PMC8295001
doi:
Substances chimiques
Benzofurans
0
Biomarkers
0
Neuroprotective Agents
0
3-n-butylphthalide
822Q956KGM
Edaravone
S798V6YJRP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4080305Informations de copyright
Copyright © 2021 Jie Yin et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Brain Behav. 2019 Dec;9(12):e01469
pubmed: 31724337
Eur J Radiol. 2019 Dec;121:108696
pubmed: 31683251
J Stroke Cerebrovasc Dis. 2017 Nov;26(11):2587-2594
pubmed: 28669654
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Aug;31(8):962-966
pubmed: 31537220
Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4431-4436
pubmed: 29077149
Rev Neurosci. 2018 Dec 19;30(1):31-44
pubmed: 30265656
Am J Vet Res. 2016 Apr;77(4):395-403
pubmed: 27027839
BJU Int. 2011 Aug;108(4):513-7
pubmed: 21176083
Balkan Med J. 2019 Oct 09;37(1):24-28
pubmed: 31594283
Clin Neurol Neurosurg. 2018 Apr;167:157-161
pubmed: 29501045
Electron Physician. 2016 Jan 15;8(1):1759-63
pubmed: 26955446
Artif Intell Med. 2016 Oct;73:45-69
pubmed: 27926381
Complement Ther Med. 2020 Aug;52:102442
pubmed: 32951710
J Stroke Cerebrovasc Dis. 2016 Dec;25(12):2953-2957
pubmed: 27693107
Medicine (Baltimore). 2018 Sep;97(39):e12642
pubmed: 30278589
Int Immunopharmacol. 2019 Dec;77:105967
pubmed: 31670091
PLoS One. 2019 Jan 3;14(1):e0209739
pubmed: 30605460
J Stroke Cerebrovasc Dis. 2013 Jul;22(5):668-74
pubmed: 22622391
Br J Radiol. 2016 Jul;89(1063):20150059
pubmed: 27168028
Comput Math Methods Med. 2015;2015:485495
pubmed: 26793269
Clin Rheumatol. 2019 May;38(5):1469-1476
pubmed: 30617597